San Diego, United States – The Department of Health – Abu Dhabi and Eli Lilly Pharmaceuticals, Eli Lilly Drugstore LLC, signed a memorandum of understanding to enhance cooperation in developing treatments for obesity and Alzheimer’s disease. This is done by employing artificial intelligence technologies and advanced clinical care, and exploring the creation of an innovative healthcare model to treat obesity. Along with a global center of excellence for Alzheimer’s disease.
The memorandum of understanding was signed during the Biotechnology Innovation Organization World Conference 2026. Which is held in San Diego, USA.
Health care model
Under the memorandum of understanding, the two parties will explore opportunities to create a health care model for treating obesity supported by artificial intelligence. It aims to provide advanced, predictive and personalized metabolic care, designed to suit the needs of the Abu Dhabi community. They will also explore opportunities to establish a global center of excellence for Alzheimer’s disease, with the aim of accelerating early detection of the disease. Promote biomarker-based diagnosis and expand access to the latest disease-modifying treatments.
Strategic paths
Cooperation will be based on two main strategic tracks:
The first involves forming a joint working group to design and develop an AI-powered care model for obesity and cardiometabolic diseases, tailored to the needs of Abu Dhabi’s population. He will benefit from the emirate’s population health data, in addition to Lili’s therapeutic expertise in the field of metabolic diseases. To support the development of advanced models for risk classification and the provision of appropriate personalized therapeutic interventions.
The second is to study the establishment of a center of excellence for Alzheimer’s disease, based on the existing cooperation between the Department of Health – Abu Dhabi and Lily Company in the field of neurodegenerative diseases. This contributes to enhancing early detection of the disease and expanding the scope of integrated digital cognitive screening. Developing care pathways across the full spectrum of Alzheimer’s disease.
